Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial
暂无分享,去创建一个
A. Auchus | S. Sen | D. Yavagal | D. Liebeskind | L. Wechsler | D. Hess | S. Savitz | R. Mays | C. Sila | W. Clark | D. Chiu | K. Uchino | G. Ford | Jeffrey D. Vest
[1] A. McConnachie,et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study , 2016, The Lancet.
[2] D. Kondziolka,et al. Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study , 2016, Stroke.
[3] J. Aronowski,et al. Acute splenic responses in patients with ischemic stroke and intracerebral hemorrhage , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] A. Demchuk,et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.
[5] C. Kleinschnitz,et al. Regulatory T Cells in Post-stroke Immune Homeostasis , 2016, Translational Stroke Research.
[6] Reint K Jellema,et al. Multipotent adult progenitor cells for hypoxic-ischemic injury in the preterm brain , 2015, Journal of Neuroinflammation.
[7] Daniel-Christoph Wagner,et al. Stem Cell–Based Tissue Replacement After Stroke: Factual Necessity or Notorious Fiction? , 2015, Stroke.
[8] Xiaoming Hu,et al. Functional Role of Regulatory Lymphocytes in Stroke: Facts and Controversies , 2015, Stroke.
[9] N. Khandelwal,et al. Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke: A Multicentric, Randomized Trial , 2014, Stroke.
[10] P. Sandercock,et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .
[11] L. Wechsler,et al. A Double-Blind Placebo-Controlled Clinical Evaluation of Multistem for the Treatment of Ischemic Stroke , 2014, International journal of stroke : official journal of the International Stroke Society.
[12] Steven C Cramer,et al. Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. , 2014, Stroke.
[13] P. Wilmarth,et al. Dissection of the Human Multipotent Adult Progenitor Cell Secretome by Proteomic Analysis , 2013, Stem cells translational medicine.
[14] Michael D Hill,et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. , 2013, The New England journal of medicine.
[15] Max Wintermark,et al. A trial of imaging selection and endovascular treatment for ischemic stroke. , 2013, The New England journal of medicine.
[16] J. Grotta,et al. Changes in Spleen Size in Patients with Acute Ischemic Stroke: A Pilot Observational Study , 2013, International journal of stroke : official journal of the International Stroke Society.
[17] J. Grotta,et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke , 2011, Annals of neurology.
[18] A. Luttun,et al. Differentiation Potential of Human Postnatal Mesenchymal Stem Cells, Mesoangioblasts, and Multipotent Adult Progenitor Cells Reflected in Their Transcriptome and Partially Influenced by the Culture Conditions , 2011, Stem cells.
[19] Michael Chopp,et al. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II , 2011, Stroke.
[20] Thorsten Dickhaus,et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes , 2011, Epigenetics.
[21] Shinil K. Shah,et al. Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes , 2010, Experimental Neurology.
[22] O. Bang,et al. A Long‐Term Follow‐Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke , 2010, Stem cells.
[23] D. Hess,et al. Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke , 2010 .
[24] S. Savitz,et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. , 2009, Stem cells and development.
[25] P. Hurn,et al. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression , 2009, Neuroscience.
[26] P. Streeter,et al. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. , 2009, Cellular immunology.
[27] A. Maitra,et al. Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell. , 2009, Journal of stem cells.
[28] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[29] P. Hurn,et al. Experimental Stroke Induces Massive, Rapid Activation of the Peripheral Immune System , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[30] C. Verfaillie,et al. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. , 2002, Experimental hematology.
[31] Catherine M. Verfaillie,et al. Pluripotency of mesenchymal stem cells derived from adult marrow , 2002, Nature.
[32] G. Albers,et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.
[33] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[34] M. Kaste,et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.